Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 29, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Oct 1, 2023 | (Q2)Jul 2, 2023 | (Q1)Apr 2, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -9.05%673.76M | -3.32%182.42M | -7.58%182.85M | -17.02%143.9M | -9.02%164.59M | -20.55%740.84M | -24.26%188.67M | -20.73%197.85M | -22.31%173.41M | 180.91M |
Operating revenue | -9.05%673.76M | -3.32%182.42M | -7.58%182.85M | -17.02%143.9M | -9.02%164.59M | -20.55%740.84M | -24.26%188.67M | -20.73%197.85M | -22.31%173.41M | --180.91M |
Cost of revenue | -2.80%477.83M | -0.00%123.04M | -1.97%126.37M | -5.91%112.08M | -3.47%116.35M | -27.91%491.59M | -34.35%123.04M | -28.80%128.91M | -26.38%119.11M | 120.53M |
Gross profit | -21.39%195.93M | -9.53%59.38M | -18.06%56.48M | -41.39%31.82M | -20.11%48.24M | -0.52%249.25M | 6.39%65.64M | 0.59%68.93M | -11.59%54.3M | 60.38M |
Operating expense | -3.27%268.24M | 4.34%70.17M | -11.05%60.46M | -1.51%68.79M | -3.42%69.89M | -2.50%277.32M | -2.92%67.25M | -3.84%67.97M | -2.27%69.85M | 72.36M |
Selling and administrative expenses | -3.54%187.16M | 5.06%50.07M | -16.25%39.55M | -0.15%48.94M | -3.03%48.6M | -1.01%194.02M | -4.60%47.66M | -1.92%47.23M | 0.67%49.02M | --50.12M |
-Selling and marketing expense | -3.20%123.69M | 5.43%32.21M | 1.07%31.2M | -8.39%29.76M | -9.89%30.53M | -8.52%127.78M | -13.55%30.55M | -9.76%30.87M | -5.97%32.48M | --33.88M |
-General and administrative expense | -4.19%63.47M | 4.39%17.86M | -48.93%8.36M | 16.03%19.19M | 11.28%18.07M | 17.63%66.24M | 17.03%17.11M | 17.31%16.36M | 16.89%16.54M | --16.24M |
Research and development costs | -2.66%81.08M | 2.59%20.1M | 0.81%20.91M | -4.70%19.85M | -8.62%20.23M | -5.82%83.3M | -3.25%19.59M | -6.45%20.74M | -6.19%20.83M | --22.13M |
Other operating expenses | ---- | ---- | ---- | ---- | 883.33%1.06M | ---- | ---- | ---- | ---- | --108K |
Operating profit | -157.69%-72.32M | -567.80%-10.79M | -511.07%-3.98M | -137.77%-36.97M | -80.78%-21.65M | 17.18%-28.06M | 78.70%-1.62M | 144.96%967K | -54.72%-15.55M | -11.98M |
Net non-operating interest income expense | 77.61%12.15M | 274.90%6.84M | ||||||||
Non-operating interest income | 77.61%12.15M | ---- | ---- | ---- | ---- | 274.90%6.84M | ---- | ---- | ---- | ---- |
Other net income (expense) | 3,977.33%85.05M | -127.16%-12.83M | 15,429.02%103.27M | -224.35%-7.18M | 102.70%2.85M | 104.18%2.09M | -29.64%-5.65M | 4.23%665K | 803.66%5.77M | 1.41M |
Gain on sale of security | -192.89%-235K | ---- | ---- | ---- | ---- | 194.19%253K | ---- | ---- | ---- | ---- |
Special income (charges) | 10,613.94%84.53M | -190.70%-4.3M | 6,278.51%99.78M | -343.61%-9.89M | ---- | 101.61%789K | 203.13%4.74M | ---1.62M | ---2.23M | ---- |
-Less:Restructuring and merger&acquisition | 13.05%4.48M | -45.43%687K | 192.90%1.07M | -24.27%1.69M | ---- | -13.44%3.96M | --1.26M | --366K | --2.23M | ---- |
-Less:Impairment of capital assets | --0 | --0 | --0 | ---- | ---- | -97.59%1.07M | --0 | --1.07M | ---- | ---- |
-Less:Other special charges | -1,428.89%-89.01M | 160.22%3.61M | -56,760.11%-100.86M | --8.2M | ---- | -29,210.00%-5.82M | ---6M | --178K | ---- | ---- |
Other non- operating income (expenses) | -27.68%755K | 22.07%-8.29M | 52.85%3.49M | -66.08%2.71M | 102.70%2.85M | 203.47%1.04M | -6,965.16%-10.64M | 257.37%2.28M | 1,075.49%8M | --1.41M |
Income before tax | 230.06%24.89M | -2,628.81%-11.46M | 5,984.13%99.29M | -351.44%-44.15M | -77.86%-18.8M | 76.67%-19.14M | 95.85%-420K | 207.87%1.63M | 10.04%-9.78M | -10.57M |
Income tax | -85.37%12.53M | -306.16%-2.58M | -83.55%14.22M | 186.33%1.03M | 82.73%-148K | 756.93%85.63M | 130.70%1.25M | 2,103.50%86.43M | 48.97%-1.19M | -857K |
Net income | 111.80%12.36M | -432.41%-8.89M | 200.32%85.07M | -426.09%-45.18M | -92.03%-18.65M | -51.86%-104.77M | 72.39%-1.67M | -3,127.45%-84.8M | -0.62%-8.59M | -9.71M |
Net income continuous Operations | 111.80%12.36M | -432.41%-8.89M | 200.32%85.07M | -426.09%-45.18M | -92.03%-18.65M | -51.86%-104.77M | 72.39%-1.67M | -3,127.45%-84.8M | -0.62%-8.59M | ---9.71M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 111.80%12.36M | -432.41%-8.89M | 200.32%85.07M | -426.09%-45.18M | -92.03%-18.65M | -51.86%-104.77M | 72.39%-1.67M | -3,127.45%-84.8M | -0.62%-8.59M | -9.71M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 111.80%12.36M | -432.41%-8.89M | 200.32%85.07M | -426.09%-45.18M | -92.03%-18.65M | -51.86%-104.77M | 72.39%-1.67M | -3,127.45%-84.8M | -0.62%-8.59M | -9.71M |
Basic earnings per share | 112.04%0.43 | -416.67%-0.31 | 203.14%2.96 | -437.93%-1.56 | -90.91%-0.63 | -50.00%-3.57 | 71.43%-0.06 | -2,970.00%-2.87 | 3.33%-0.29 | -0.33 |
Diluted earnings per share | 111.76%0.42 | -416.67%-0.31 | 201.05%2.9 | -437.93%-1.56 | -90.91%-0.63 | -50.00%-3.57 | 71.43%-0.06 | -2,970.00%-2.87 | 3.33%-0.29 | -0.33 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |